Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

Sherwyn L. Schwartz; Bola Akinlade; Sally Klasen; Donna Kowalski; Wenhui Zhang; Wim Wilpshaar

doi:10.1089/dia.2011.0012

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

Diabetes Technology & Therapeutics ◽

10.1089/dia.2011.0012 ◽

2011 ◽

Vol 13 (12) ◽

pp. 1219-1227 ◽

Cited By ~ 52

Author(s):

Sherwyn L. Schwartz ◽

Bola Akinlade ◽

Sally Klasen ◽

Donna Kowalski ◽

Wenhui Zhang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Sodium Dependent

Download Full-text

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

Drug Metabolism and Disposition ◽

10.1124/dmd.111.040675 ◽

2011 ◽

Vol 39 (9) ◽

pp. 1609-1619 ◽

Cited By ~ 53

Author(s):

Amit S. Kalgutkar ◽

Meera Tugnait ◽

Tong Zhu ◽

Emi Kimoto ◽

Zhuang Miao ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Sodium Dependent ◽

Preclinical Species ◽

Clinical Candidate

Download Full-text

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01462.x ◽

2011 ◽

Vol 14 (1) ◽

pp. 15-22 ◽

Cited By ~ 40

Author(s):

R. L. Dobbins ◽

R. O’Connor-Semmes ◽

A. Kapur ◽

C. Kapitza ◽

G. Golor ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Serum Glucose ◽

Selective Inhibitor ◽

Sodium Dependent ◽

Remogliflozin Etabonate

Download Full-text

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Diabetes Obesity and Metabolism ◽

10.1111/dom.13887 ◽

2019 ◽

Vol 22 (2) ◽

pp. 191-202 ◽

Cited By ~ 2

Author(s):

Hong Zhang ◽

Xiaoxue Zhu ◽

Xiaojiao Li ◽

Hong Chen ◽

Min Wu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Review for "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus"

10.1111/dom.13887/v2/review1 ◽

2019 ◽

Author(s):

Kyu Cho

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Decision letter for "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus"

10.1111/dom.13887/v2/decision1 ◽

2019 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Review for "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus"

10.1111/dom.13887/v1/review3 ◽

2019 ◽

Author(s):

Kyu Yong Cho

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Decision letter for "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus"

10.1111/dom.13887/v3/decision1 ◽

2019 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text

Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Journal of Diabetes Investigation ◽

10.1111/jdi.12156 ◽

2013 ◽

Vol 5 (4) ◽

pp. 382-391 ◽

Cited By ~ 59

Author(s):

Atsunori Kashiwagi ◽

Kenichi Kazuta ◽

Satoshi Yoshida ◽

Itsuro Nagase

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycemic Control ◽

Japanese Patients ◽

Double Blind ◽

Sodium Dependent

Download Full-text

Faculty Opinions recommendation of Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732443634.793558337 ◽

2019 ◽

Author(s):

Carlos Aguilar-Salinas

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bile Acid ◽

Controlled Trial ◽

Healthy Adults ◽

Sodium Dependent ◽

Bile Acid Transporter ◽

Acid Transporter

Download Full-text

Review for "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus"

10.1111/dom.13887/v2/review2 ◽

2019 ◽

Author(s):

Osamu Cynshi

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Selective Inhibitor ◽

Pharmacokinetics And Pharmacodynamics

Download Full-text